HKU Scholars Hub: Browsing DSpace

Browsing by Author Brown, NA

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 20 of 21 next >

Title	Author(s)	Issue Date	Views
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Journal:Gastroenterology	Lai, CL Leung, N Teo, EK Tong, M Wong, F Hann, HW Han, S Poynard, T Myers, M Chao, G Lloyd, D Brown, NA	2005	216
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B Journal:Gastroenterology	Liaw, Y Gane, E Leung, N Zeuzem, S Wang, Y Lai, CL Heathcote, EJ Manns, M Bzowej, N Niu, J Han, S Hwang, SG Cakaloglu, Y Tong, MJ Papatheodoridis, G Chen, Y Brown, NA Albanis, E Galil, K Naoumov, NV	2009
76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine Proceeding/Conference:Journal of Hepatology	Marcellin, P Chan, HLY Lai, CL Cho, M Moon, YM Chao, YC Heathcote, J Myers, R Harb, G Brown, NA	2007	136
Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the globe study Proceeding/Conference:Journal of Hepatology	Pane, E Lai, CL Min, A Heathcote, I Poynard, T Kurdas, OO Grange, JD Brown, NA	2007	124
The authors reply Journal:New England Journal of Medicine	Lai, CL Gane, E Brown, NA	2008	133
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection Journal:Hepatology	Lai, CL Lim, SG Brown, NA Zhou, XJ Lloyd, DM Lee, YM Yuen, MF Chao, GC Myers, MW	2004	213
Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelines Proceeding/Conference:Journal of Hepatology	Rasenack, J Poynard, T Lai, CL Gane, E Brown, NA Heathcote, J	2007	124
Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Lim, SG Lai, CL Myers, M Yuen, RMF Wai, CT Lloyd, D Pietropalolo, K Zhou, XJ Chao, G Brown, NA	2005	210
In hepatitis B patients treated with either adefovir or telbivudine, maximal early hbv suppression at 24 weeks predicts optimal one-year efficacy Proceeding/Conference:Journal of Hepatology	Marcellin, P Chan, HLY Lai, CL Clio, M Heathcote, I Moon, YM Chao, YC Myers, R Harb, G Brown, NA	2007	154
Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B Proceeding/Conference:Interscience Conference on Antimicrobial Agents and Chemotherapy	Dienstag, JL Lai, CL Hann, HWL Leung, NWY Grimm, IS Schiff, E Woessner, M Dent, J Crowther, L Brown, NA	1999	119
Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications Journal:Antimicrobial Agents and Chemotherapy	Zhou, XJ Lim, SG Lloyd, DM Chao, GC Brown, NA Lai, CL	2006
Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results Proceeding/Conference:Gastroenterology	Lai, CL Leung, NW Teo, EK Tong, M Wong, F Hann, HWY Han, SH Poynard, T Qiao, X Pietropaolo, K Lloyd, D Brown, NA	2005
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Journal:Hepatology	Perrillo, RP Lai, CL Liaw, YF Dienstag, JL Schiff, ER Schalm, SW Heathcote, EJenny Brown, NA Atkins, M Woessner, M Gardner, SD	2002	139
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results Proceeding/Conference:Hepatology	Bzowej, N Chan, HLY Lai, CL Cho, M Moon, YM Chao, YC Heathcote, EJ Myers, R Minuk, G Marcellin, P Jeffers, L Sievert, W Kaiser, R Harb, G Chao, GC Brown, NA	2006	126
Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): Results of a dose-escalation trial Proceeding/Conference:Hepatology	Lai, CL Myers, MW Pow, DM Brown, NA Lee, YM Yuen, RMF Lim, SG	2001	111
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients Proceeding/Conference:Hepatology	DiBisceglie A, A Lai, CL Gane, E Chen, YC Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Zeuzem, S Rasenack, J Bzowej, N Han, SH Naoumov, N Hwang, SG Lim, SG Chao, GC Fielman, BA Brown, NA Study Group The GLOBE,	2006	100
Telbivudine versus lamivudine in patients with chronic hepatitis B Journal:New England Journal of Medicine	Lai, CL Gane, E Liaw, YF Hsu, CW Thongsawat, S Wang, Y Chen, Y Heathcote, EJ Rasenack, J Bzowej, N Naoumov, NV Di Bisceglie, AM Zeuzem, S Moon, YM Goodman, Z Chao, G Constance, BF Brown, NA	2007	135
Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response Proceeding/Conference:Hepatology International	Lai, CL Gane, E Hsu, CW Chen, YC Thongsawat, S Wang, Y Chen, Y Naoumov, N Han, SH Hwang, SG Lim, SG Brown, NA	2007	163
Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial Journal:Annals of Internal Medicine	Chan, HLY Heathcote, EJ Marcellin, P Lai, CL Cho, M Moon, YM Chao, YC Myers, RP Minuk, GY Jeffers, L Sievert, W Bzowej, N Harb, G Kaiser, R Qiao, XJ Brown, NA Crawford, D Lim, SG Chutaputti, A Poynard, T	2007	112
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine Proceeding/Conference:Hepatology	Lai, CL Gane, E Hsu, CW Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Rasenack, J Bzowej, N Naoumov, N Zeuzem, S Di Bisceglie, A Chao, GC Barbara, A Constance, F Brown, NA Study Group The GLOBE.,	2006	162

Showing results 1 to 20 of 21 next >